PDS Biotechnology Co. (NASDAQ:PDSB – Get Rating) has been given a consensus rating of “Buy” by the eight research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $21.20.
Separately, StockNews.com upgraded shares of PDS Biotechnology to a “sell” rating in a research report on Saturday, April 9th.
NASDAQ:PDSB opened at $5.16 on Monday. The firm’s 50 day simple moving average is $5.95 and its 200 day simple moving average is $7.99. PDS Biotechnology has a one year low of $4.10 and a one year high of $17.85.
Large investors have recently added to or reduced their stakes in the company. Voloridge Investment Management LLC increased its stake in shares of PDS Biotechnology by 279.2% in the 3rd quarter. Voloridge Investment Management LLC now owns 49,191 shares of the company’s stock valued at $733,000 after acquiring an additional 36,219 shares in the last quarter. Trexquant Investment LP bought a new stake in shares of PDS Biotechnology in the 3rd quarter valued at $632,000. Cubist Systematic Strategies LLC increased its stake in shares of PDS Biotechnology by 187.0% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 71,618 shares of the company’s stock valued at $1,067,000 after acquiring an additional 46,665 shares in the last quarter. Jump Financial LLC bought a new stake in shares of PDS Biotechnology in the 3rd quarter valued at $393,000. Finally, Valeo Financial Advisors LLC increased its stake in shares of PDS Biotechnology by 35.7% in the 4th quarter. Valeo Financial Advisors LLC now owns 21,570 shares of the company’s stock valued at $175,000 after acquiring an additional 5,670 shares in the last quarter. Institutional investors own 23.91% of the company’s stock.
PDS Biotechnology Company Profile (Get Rating)
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer.
- Get a free copy of the StockNews.com research report on PDS Biotechnology (PDSB)
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- MarketBeat Podcast: 3 Stocks Flashing Buy Signals
Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.